HK1190709A1 - Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors iii n-(1h--4-)[12-a]-3- - Google Patents

Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors iii n-(1h--4-)[12-a]-3-

Info

Publication number
HK1190709A1
HK1190709A1 HK14103774.0A HK14103774A HK1190709A1 HK 1190709 A1 HK1190709 A1 HK 1190709A1 HK 14103774 A HK14103774 A HK 14103774A HK 1190709 A1 HK1190709 A1 HK 1190709A1
Authority
HK
Hong Kong
Prior art keywords
indazol
imidazo
pyridine
substituted
tyrosine kinase
Prior art date
Application number
HK14103774.0A
Other languages
English (en)
Chinese (zh)
Inventor
Mark Laurence Boys
Robert Kirk Delisle
Erik James Hicken
April L Kennedy
David A Mareska
Fredrik P Marmsater
Mark C Munson
Brad Newhouse
Bryson Rast
James P Rizzi
Martha E Rodriguez
George T Topalov
Qian Zhao
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of HK1190709A1 publication Critical patent/HK1190709A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK14103774.0A 2010-12-13 2014-04-22 Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors iii n-(1h--4-)[12-a]-3- HK1190709A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42254710P 2010-12-13 2010-12-13
PCT/US2011/064549 WO2012082689A1 (en) 2010-12-13 2011-12-13 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
HK1190709A1 true HK1190709A1 (en) 2014-07-11

Family

ID=45478484

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14103774.0A HK1190709A1 (en) 2010-12-13 2014-04-22 Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors iii n-(1h--4-)[12-a]-3-

Country Status (32)

Country Link
US (3) US9174981B2 (pt)
EP (1) EP2651939B1 (pt)
JP (3) JP5868996B2 (pt)
KR (1) KR101974665B1 (pt)
CN (3) CN103347882B (pt)
AU (3) AU2011344001B2 (pt)
BR (1) BR112013014854B1 (pt)
CA (2) CA2821712C (pt)
CL (1) CL2013001712A1 (pt)
CO (1) CO6751248A2 (pt)
CR (1) CR20130349A (pt)
DK (1) DK2651939T3 (pt)
ES (1) ES2540996T3 (pt)
HK (1) HK1190709A1 (pt)
HR (1) HRP20150571T1 (pt)
HU (1) HUE025416T2 (pt)
IL (1) IL226911A (pt)
ME (1) ME02172B (pt)
MX (1) MX2013006763A (pt)
MY (1) MY172110A (pt)
NZ (1) NZ613235A (pt)
PL (1) PL2651939T3 (pt)
PT (1) PT2651939E (pt)
RS (1) RS54070B1 (pt)
RU (1) RU2591195C2 (pt)
SG (1) SG191129A1 (pt)
SI (1) SI2651939T1 (pt)
SM (1) SMT201500165B (pt)
TW (1) TWI527813B (pt)
UA (1) UA112425C2 (pt)
UY (1) UY33801A (pt)
WO (1) WO2012082689A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601376A (en) * 2009-12-21 2014-03-28 Array Biopharma Inc Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors
WO2012082689A1 (en) 2010-12-13 2012-06-21 Array Biopharma Inc. SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN104496891A (zh) * 2014-12-06 2015-04-08 哈尔滨工业大学 吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法
CN104974078A (zh) * 2015-06-25 2015-10-14 黄荣辉 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
KR20180039117A (ko) 2015-08-11 2018-04-17 네오메드 인스티튜트 아릴-치환된 디히드로퀴놀리논, 그의 제조법 및 제약으로서의 그의 용도
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
EP3334719B1 (en) 2015-08-12 2021-09-15 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
EP3371172B1 (en) * 2015-11-02 2021-10-20 Genase Therapeutics B.V. Tetrahydroindazoles and medical uses thereof
CN105198799A (zh) * 2015-11-03 2015-12-30 江苏梦得电镀化学品有限公司 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
RU2744988C2 (ru) * 2016-06-14 2021-03-17 Новартис Аг Соединения и композиции для подавления активности shp2
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
WO2018019291A1 (en) * 2016-07-29 2018-02-01 The Hong Kong University Of Science And Technology C(sp3)-c(sp2) cross-coupling reaction of organozinc reagents and heterocyclic (pseudo)halides
EP3535243B1 (en) 2016-11-04 2021-12-15 Auckland Uniservices Limited Substituted 9h-xanthen-9-one, 9h-thioxanthen-9-one and acridin-9(10h)-one derivatives and related compounds csf-1r inhibitors for the treatment of cancer
ES2954879T3 (es) * 2016-11-28 2023-11-27 Eisai R&D Man Co Ltd Sales de derivado de indazol y cristales de las mismas
ES2962961T3 (es) 2017-07-28 2024-03-22 Yuhan Corp Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo
AU2019234670B2 (en) 2018-03-13 2023-11-23 Takeda Pharmaceutical Company Limited Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
CN111410654B (zh) * 2019-01-19 2022-05-17 江苏新元素医药科技有限公司 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
FI4031547T3 (fi) 2019-09-18 2024-09-16 Takeda Pharmaceutical Company Ltd Plasman kallikreiinin estäjiä ja niiden käyttötapoja
JP2022549601A (ja) 2019-09-18 2022-11-28 武田薬品工業株式会社 ヘテロアリール血漿カリクレインインヒビター

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO2003099811A1 (en) 2002-05-23 2003-12-04 Cytopia Pty Ltd Kinase inhibitors
AU2007337895C1 (en) 2006-12-22 2014-07-31 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
UA101611C2 (ru) * 2007-04-03 2013-04-25 Аррей Байофарма Инк. СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
FR2925901B1 (fr) 2008-01-02 2011-03-04 Sanofi Aventis DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
JP5502076B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規化合物
TW201105669A (en) * 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
NZ601376A (en) * 2009-12-21 2014-03-28 Array Biopharma Inc Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors
WO2012082689A1 (en) * 2010-12-13 2012-06-21 Array Biopharma Inc. SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
CN102250246A (zh) * 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用

Also Published As

Publication number Publication date
JP5868996B2 (ja) 2016-02-24
AU2016222468A1 (en) 2016-09-22
BR112013014854A2 (pt) 2016-10-18
CA3027814A1 (en) 2012-06-21
RU2013132758A (ru) 2015-01-20
UA112425C2 (uk) 2016-09-12
CA2821712A1 (en) 2012-06-21
MY172110A (en) 2019-11-14
CN109608449A (zh) 2019-04-12
EP2651939B1 (en) 2015-04-08
CN105924437A (zh) 2016-09-07
WO2012082689A1 (en) 2012-06-21
DK2651939T3 (en) 2015-06-01
US20130274244A1 (en) 2013-10-17
HUE025416T2 (en) 2016-02-29
TW201305156A (zh) 2013-02-01
SMT201500165B (it) 2015-09-07
AU2016222468B2 (en) 2017-12-21
US10669269B2 (en) 2020-06-02
PT2651939E (pt) 2015-08-04
RS54070B1 (en) 2015-10-30
IL226911A (en) 2016-09-29
CN105924437B (zh) 2018-11-30
RU2591195C2 (ru) 2016-07-10
KR101974665B1 (ko) 2019-05-02
SG191129A1 (en) 2013-07-31
CO6751248A2 (es) 2013-09-16
AU2018201903A1 (en) 2018-04-12
CL2013001712A1 (es) 2013-12-06
EP2651939A1 (en) 2013-10-23
CN103347882A (zh) 2013-10-09
ES2540996T3 (es) 2015-07-15
PL2651939T3 (pl) 2015-10-30
US20180086758A1 (en) 2018-03-29
UY33801A (es) 2013-06-28
CN103347882B (zh) 2016-05-11
US20160002232A1 (en) 2016-01-07
US9174981B2 (en) 2015-11-03
CR20130349A (es) 2013-08-09
JP2013545808A (ja) 2013-12-26
HRP20150571T1 (en) 2015-07-03
KR20140014109A (ko) 2014-02-05
CA2821712C (en) 2019-02-12
AU2018201903B2 (en) 2019-09-19
ME02172B (me) 2015-10-20
MX2013006763A (es) 2014-01-08
SI2651939T1 (sl) 2015-07-31
TWI527813B (zh) 2016-04-01
JP2018065835A (ja) 2018-04-26
NZ613235A (en) 2015-04-24
AU2011344001B2 (en) 2016-06-30
BR112013014854A8 (pt) 2018-03-27
US9809590B2 (en) 2017-11-07
JP2016040303A (ja) 2016-03-24
BR112013014854B1 (pt) 2020-12-08

Similar Documents

Publication Publication Date Title
HK1190709A1 (en) Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors iii n-(1h--4-)[12-a]-3-
HUS2000006I1 (hu) Szubsztituált pirazolo[1,5-a]pirimidin vegyületek mint TRK kináz inhibitorok
HK1176928A1 (en) Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors cfms n-(1h--4-)[12-a]-3-
HRP20130660T1 (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
ZA201200982B (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
IL233067A0 (en) Pyrazole [a-1,5]pyridine is converted as tropomyosin receptor kinase (trx) inhibitors
PL2350075T3 (pl) Podstawione związki imidazo[1,2b]pirydazynowe jako inhibitory kinaz Trk
HK1145496A1 (zh) 作為蛋白酪氨酸激酶抑制劑的雙環雜環化合物
HK1145495A1 (zh) 作為蛋白酪氨酸激酶抑制劑的雙環雜環化合物
IL214426A0 (en) [1,2,4] triazollo [1,5-a] pyridines as kinase inhibitors
EP2523552A4 (en) PYRAZOLO- [1,5-A] PYRIMIDINE AS MARK HEMMER
EP2490693A4 (en) Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211212